Inhibitory effect of copper(II) on zinc(II)-induced aggregation of amyloid beta-peptide.
Aggregation of amyloid beta-peptide (Abeta), a key pathological event in Alzheimer's disease, has been shown in vitro to be profoundly promoted by Zn(II). This fact suggests that some factors in the normal brain protect Abeta from the Zn(II)-induced aggregation. We demonstrate for the first time that Cu(II) effectively inhibits the Abeta aggregation by competing with Zn(II) for histidine residues. The Raman spectrum of a metal-Abeta complex in the presence of both Zn(II) and Cu(II) shows that the cross-linking of Abeta through binding of Zn(II) to the N(tau) atom of histidine is prevented by chelation of Cu(II) by the N(pi) atom of histidine and nearby amide nitrogens. The inhibitory effect is strongest at a Cu/Abeta molar ratio of around 4. Above this ratio, Cu(II) itself promotes the Abeta aggregation by binding to the phenolate oxygen of Tyr10. These results emphasize the importance of regulation of Cu(II) levels to inhibit Abeta aggregation, and are consistent with an altered metal homeostasis in Alzheimer's disease.
Suzuki
K
K
Graduate School of Pharmaceutical Sciences, Tohoku University, Aobayama, Sendai, 980-8578, Japan.
Miura
T
T
Takeuchi
H
H
D016229:Amyloid beta-Peptides / Q000737:chemistry*; D002413:Cations, Divalent; D003300:Copper; D010446:Peptide Fragments / Q000737:chemistry*; D012995:Solubility; D013059:Spectrum Analysis, Raman; D015032:Zinc
D016229:Amyloid beta-Peptides; D002413:Cations, Divalent; D010446:Peptide Fragments; D003300:Copper; D015032:Zinc